AbbVie Inc. reported that US sales erosion of top-seller Humira (adalimumab) due to domestic biosimilar competition is proceeding very close to expectations on 27 April, but analysts focused on Humira successors Rinvoq and Skyrizi posting quarterly sales numbers below consensus, although year-over-year growth remained strong.
On its first quarter sales and earnings call, AbbVie noted that Humira – now facing competition from Amgen, Inc.’s Amjevita, with multiple biosimilar versions of adalimumab set to launch later this year – saw a 26.1% year-over-year domestic sales decline during the quarter, still bringing in nearly $2.95bn
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?